Episode 12: Tebentafusp-tebn - The Backstory
Upon completion of this activity, participants will be able to:
- Articulate the reasoning behind an FDA oncology drug approval.
- Identify the relevant sections of the drug USPI where information is located.
- Integrate this information into their clinical practice.
Review video content here.
Time to Complete Activity: 75
Get it
In This Episode:
Timil Patel, MD – Medical Oncologist, Division of Oncology 3, Oncology Center of Excellence
Jamie Brewer, MD - Medical Oncologist and Acting Clinical Team Lead, Division of Oncology 3, Office of Oncologic Diseases
Mark Moyer - Senior Vice President, Head of Regulatory Sciences, Immunocore
Richard D. Carvajal, MD - Deputy Physician-in-Chief, Director of Hematology/Oncology, Northwell Health Cancer Institute
Jianan (Carlos) Sheng - Patient and Clinical Trial Participant
Carol Ann Wiggs - Clinical Research Nurse Manager, Duke Cancer Institute
Heather Armbruster, PharmD, BCOP – Outpatient Clinical Pharmacy Manager, James Cancer Hospital & Solove Research Institute